BRPI0409402A - derivados de 7-([1,4]dioxan-2-il)-benzotiazol como ligante de receptor de adenosina - Google Patents

derivados de 7-([1,4]dioxan-2-il)-benzotiazol como ligante de receptor de adenosina

Info

Publication number
BRPI0409402A
BRPI0409402A BRPI0409402-6A BRPI0409402A BRPI0409402A BR PI0409402 A BRPI0409402 A BR PI0409402A BR PI0409402 A BRPI0409402 A BR PI0409402A BR PI0409402 A BRPI0409402 A BR PI0409402A
Authority
BR
Brazil
Prior art keywords
unsubstituted
mono
dioxan
disubstituted
lower alkyl
Prior art date
Application number
BRPI0409402-6A
Other languages
English (en)
Inventor
Alexander Flohr
Roger David Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0409402A publication Critical patent/BRPI0409402A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE 7-(¢1,4!DIOXAN-2-IL)-BENZOTIAZOL COMO LIGANTE DE RECEPTOR DE ADENOSINA". A presente invenção refere-se aos compostos da fórmula geral onde R¬ 1¬ é um grupo dioxano, conforme descrito na reivindicação 1 e R¬ 2¬ é - (CH~ 2~)~ n~-Piridin-2,3 ou 4-ila substituída ou não substituída; ou é -(CH~ 2~)~ n~-piperidina-1-ila não substituída ou mono- ou dissubstituída; ou é -(CH~ 2~)~ n~-fenila não substituída ou mono-ou dissubstituída; ou é benzo¢1.3!dioxol-5-ila; ou - (CH~ 2~ )~ n~-morfolinila; ou -(CH~ 2~)~ n~-tetrahidropiran-4-ila; ou -(CH~ 2~)~ n~-O-alquila inferior; ou -(CH~ 2~)~ n~-cicloalquila; ou -(CH~ 2~)~ n~-C(O)-NR<39>R<39><39>; ou -(CH~ 2~)~ n~-2-oxo-pirrolidin-1-ila; ou -(CH~ 2~)~ n~NR<39>R<39><39>; ou -2-oxa-5-aza-iciclo¢2.2.1!heptano-5-ila; ou -1-oxa-8-aza-espiro¢4.5!decano-8-ila; e R<39>e R<39><39> são independentemente um do outro alquila inferior, -(CH~ 2~)~ o~-O-alquila inferior, cicloalquila mono- ou dissubstituída; e n é 0, 1, 2 ou 3; m é O ou 1; e o é 1 ou 2; e aos sais de adição de ácido farmaceuticamente aceitáveis dos mesmos. Foi verificado que os compostos da fórmula geral 1 são ligantes receptores de adenosina com uma boa afinidade em relação ao receptor A~ 2A~ e uma alta seletividade em relação aos receptores A~ 1~- e A~ 3~.
BRPI0409402-6A 2003-04-14 2004-04-07 derivados de 7-([1,4]dioxan-2-il)-benzotiazol como ligante de receptor de adenosina BRPI0409402A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03008038 2003-04-14
PCT/EP2004/003734 WO2004089949A1 (en) 2003-04-14 2004-04-07 7-([1,4]dioxan-2-yl)-benzothiazole derivatives as adenosine receptor ligands

Publications (1)

Publication Number Publication Date
BRPI0409402A true BRPI0409402A (pt) 2006-04-25

Family

ID=33104055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409402-6A BRPI0409402A (pt) 2003-04-14 2004-04-07 derivados de 7-([1,4]dioxan-2-il)-benzotiazol como ligante de receptor de adenosina

Country Status (20)

Country Link
US (1) US6872833B2 (pt)
EP (1) EP1615919B1 (pt)
JP (1) JP4426569B2 (pt)
KR (1) KR100700422B1 (pt)
CN (1) CN100447140C (pt)
AR (1) AR043845A1 (pt)
AT (1) ATE370947T1 (pt)
AU (1) AU2004228193B2 (pt)
BR (1) BRPI0409402A (pt)
CA (1) CA2520852C (pt)
CL (1) CL2004000761A1 (pt)
CO (1) CO5640107A2 (pt)
DE (1) DE602004008447T2 (pt)
ES (1) ES2291868T3 (pt)
MX (1) MXPA05011102A (pt)
NO (1) NO20054794L (pt)
RU (1) RU2005135154A (pt)
TW (1) TW200427685A (pt)
WO (1) WO2004089949A1 (pt)
ZA (1) ZA200508180B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622486B2 (en) * 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
US7756037B2 (en) * 2006-08-14 2010-07-13 Cisco Technology, Inc. Oversubscription of guaranteed bandwidth
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
EP2970281A4 (en) * 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZENE COMPOUNDS
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
IL272284B2 (en) * 2017-08-01 2024-01-01 Merck Patent Gmbh History of thiazolopyridines, their preparation and pharmaceutical preparations containing them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2003182A3 (cs) * 2000-06-21 2003-06-18 F. Hoffmann-La Roche Ag Deriváty benzothiazolu
CA2442476A1 (en) * 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6734179B2 (en) 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles

Also Published As

Publication number Publication date
KR100700422B1 (ko) 2007-03-28
NO20054794L (no) 2005-10-27
CO5640107A2 (es) 2006-05-31
DE602004008447T2 (de) 2008-05-21
TW200427685A (en) 2004-12-16
KR20050111795A (ko) 2005-11-28
AR043845A1 (es) 2005-08-17
WO2004089949A1 (en) 2004-10-21
CA2520852A1 (en) 2004-10-21
CL2004000761A1 (es) 2005-02-04
CN1774437A (zh) 2006-05-17
US6872833B2 (en) 2005-03-29
EP1615919A1 (en) 2006-01-18
US20040204584A1 (en) 2004-10-14
ES2291868T3 (es) 2008-03-01
AU2004228193B2 (en) 2009-07-23
ATE370947T1 (de) 2007-09-15
RU2005135154A (ru) 2006-06-27
AU2004228193A1 (en) 2004-10-21
CN100447140C (zh) 2008-12-31
MXPA05011102A (es) 2005-12-12
DE602004008447D1 (de) 2007-10-04
CA2520852C (en) 2011-10-11
JP2006522765A (ja) 2006-10-05
EP1615919B1 (en) 2007-08-22
ZA200508180B (en) 2007-03-28
JP4426569B2 (ja) 2010-03-03

Similar Documents

Publication Publication Date Title
Ishida et al. Antitumor agents 201.1 Cytotoxicity of harmine and β-carboline analogs
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
BRPI0606895A2 (pt) novos compostos com efeito terapêutico
BRPI0606644A2 (pt) derivados de 4-carboxamida tiazola
CR8530A (es) Intermediarios de quinolona como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
BRPI0506719A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0407493A (pt) derivados heterociclil-3-sulfinilazaindol ou -azaindazol como ligantes de 5-hidroxitriptamina-6
BR9911182A (pt) Composto, uso do mesmo, processo para o tratamento de um mamìfero, incluindo homem, de condições suscetìveis de melhora por um agonista de beta-adrenorreceptor atìpico, composição farmacêutica, e, processo para a preparação de um composto.
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
BRPI0517461A (pt) compostos farmacêuticos
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
BRPI0507620A (pt) monÈmeros de acrilamida contendo funcionalidades hidroxila e silìcio e polìmeros feitos a partir dos mesmos
BR112012003955A2 (pt) compostos heterocíclicos tricíclicos como inibidores da fosfoinositídeos 3-quinase
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
BR112015000019A2 (pt) corantes azo dispersos, processo para preparação dos mesmos e uso dos mesmos
AR064640A1 (es) DERIVADOS DE PIRIDO[2, 3-D]PIRIMIDIN-4, 7(3H, 8H)-DIONA, METODOS PARA SU PREPARACION E INTERMEDIARIOS DE SINTESIS, COMPOSICIONES FARMACEUTICAS, KIT DE ELEMENTOS Y ARTíCULO MANUFACTURADO QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR M
BRPI0615248A2 (pt) derivado tendo atividade agonista de ppar
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
BRPI0409402A (pt) derivados de 7-([1,4]dioxan-2-il)-benzotiazol como ligante de receptor de adenosina
BR0311315A (pt) Sulfonas aromáticas e sua utilização médica
BR0305247A (pt) Processo de preparação de copolìmeros de etileno
BRPI0809983A2 (pt) Quinolinas e seu uso terapêutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.